---
title: "Achieve Life Sciences Reaffirmed at Buy as Financing, Leadership Refresh, and Strong Cytisinicline Data Support Unchanged $10 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286303279.md"
description: "Maxim Group analyst Jason McCarthy reaffirmed a Buy rating on Achieve Life Sciences with a $10 price target, citing the company's strengthened financial position and promising clinical data for cytisinicline. The recent $354M financing extends the company's runway for U.S. approval and a new Phase 3 trial. The leadership refresh and positive Phase 3 data support confidence in the drug's commercialization. Lake Street also maintained a Buy rating with an $11 price target."
datetime: "2026-05-13T18:35:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286303279.md)
  - [en](https://longbridge.com/en/news/286303279.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286303279.md)
---

# Achieve Life Sciences Reaffirmed at Buy as Financing, Leadership Refresh, and Strong Cytisinicline Data Support Unchanged $10 Price Target

Maxim Group analyst Jason McCarthy maintained a Buy rating on Achieve Life Sciences yesterday and set a price target of $10.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Jason McCarthy has given his Buy rating due to a combination of factors, including Achieve’s strengthened financial position and advancing clinical program. The recent $354M private financing, with $180M received upfront and the rest in milestone-linked warrants, materially extends the company’s runway to support cytisinicline through potential U.S. approval and a new Phase 3 trial targeting e‑cigarette and vaping dependence.

The company has also refreshed its leadership team and board ahead of the anticipated launch, while preparing for an NDA resubmission in 4Q26 after addressing the manufacturing-related CRL. Cytisinicline’s robust Phase 3 ORCA-2 and ORCA-3 data, showing materially higher quit rates versus placebo with a favorable safety profile, underpin his confidence that the drug can be approved and successfully commercialized, supporting the unchanged $10 price target.

McCarthy covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Medicus Pharma Ltd, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of \-14.2% and a 32.87% success rate on recommended stocks.

In another report released today, Lake Street also maintained a Buy rating on the stock with a $11.00 price target.

### Related Stocks

- [ACHV.US](https://longbridge.com/en/quote/ACHV.US.md)
- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [MDCX.US](https://longbridge.com/en/quote/MDCX.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)
- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News](https://longbridge.com/en/news/286952863.md)
- [Achieve Life Sciences Announces Up to $354 Million Private Placement | ACHV Stock News](https://longbridge.com/en/news/283004765.md)
- [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [Jacobs Growth Could Improve on Data Centers, Life Sciences Demand, RBC Says](https://longbridge.com/en/news/286945689.md)